Depression FDA - Search News

FDA Approves ‘Spravato’ Nasal Spray

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Popular Science · 3d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

CNN on MSN · 4d

FDA approves standalone use of J&J’s ketamine-derived depression treatment

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

mic4d

A Nasal Spray For Depression? FDA Gives Its Approval

The U.S. Food and Drug Administration (FDA ... This innovative treatment is poised to change the landscape of depression management, particularly for those grappling with treatment-resistant ...

Newsweek3d

FDA Approves Nasal Spray for Depression

This new treatment could help bring relief for millions of Americans struggling with depression. The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

FDA Approves ‘Spravato’ Nasal Spray

Trending now